Prostatitis -- trovan warning

Home


Trovan Information
On June 9, 1999, FDA issued a public health advisory to physicians concerning the risks of liver toxicity associated with the use of Trovan (trovafloxacin, an oral antibiotic) and Trovan-IV (alatrofloxacin, the intranvenous formulation of the drug). Trovan is an antibiotic used to treat many different types of infections. Trovafloxacin was approved for marketing in December, 1997, and became available on the market in February, 1998. Based on new safety data related to serious liver injury, FDA is advising physicians that trovafloxacin should be reserved for use only in patients who meet the specific criteria outlined in the linked public health advisory.

This information is forwarded to you by the Prostatitis Foundation. We do not provide medical advice. We distribute literature and information relevant to prostatitis. While we encourage all research we do not endorse any doctor, medicine or treatment protocol. Consult with your own physician.
© 2002 The Prostatitis Foundation
	Further Contact:(click on words or mailbox) This page was created by Ideasmith®. Add to this site

Trovan Information